Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Macular EdemaBranch Retinal Vein Occlusion
Interventions
PROCEDURE

Arteriovenous Crossing Sheathotomy

In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.

PROCEDURE

Intravitreal Triamcinolone Acetonide Injection

The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.

Trial Locations (1)

120-752

Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT00612261 - Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter